Boston Scientific Stock
€89.60
Your prediction
Boston Scientific Stock
Pros and Cons of Boston Scientific in the next few years
Pros
Cons
Performance of Boston Scientific vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Boston Scientific | -0.440% | -3.240% | -2.183% | 28.000% | 2.989% | 141.347% | 160.541% |
Veeva Systems A | -0.320% | 1.623% | 22.266% | 47.251% | 23.228% | 41.581% | 39.359% |
Thermo Fisher Scientific Inc. | 1.340% | -0.550% | -1.426% | -33.800% | -29.378% | -32.157% | 12.416% |
Waters Corp. | 1.300% | -1.465% | 3.791% | 9.561% | -12.992% | 1.326% | 72.849% |

sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Analyzing the financials of Boston Scientific Corporation (BSX) reveals a complex picture of a company operating in the Healthcare Equipment & Supplies sector. With a strong market capitalization eyeing \$101.65 billion, Boston Scientific displays robust revenue metrics alongside significant growth in earnings over the past few years. However, the financial landscape also presents certain challenges, particularly regarding profitability margins and quite high valuation ratios. The comprehensive examination of its balance sheet, cash flow statements, income statements, and financial ratios paints a vivid portrayal of the company’s operational efficiency and market positioning.
Robust Revenue Growth: Boston Scientific has shown impressive revenue growth, with a trailing twelve-month revenue of over \$15.22 billion and a quarterly revenue growth year over year of 14.5%. This growth indicates strong market demand for its products, reflecting a company that can effectively expand and capture more market share.
Strong Profit Margins: The profit margin sits at 12%, which is quite competitive given the industry standards. Additionally, the operating margin of 20.39% demonstrates an efficient cost structure relative to its revenues. This is a sign of effective management that is keeping its operating costs under control while still generating substantial sales.
Comments
News

Boston Scientific Stock: Executives Sell Shares Near Record High
Boston Scientific Corporation's stock continues to demonstrate remarkable momentum, trading close to its 52-week peak of $107.17 and boasting an impressive year-to-date performance exceeding 62%